ποΈ Verified NIH Record β’ Updated 2025-11-02
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors (NCT06148636)
A Phase 1, First-in-human Clinical Trial of [212Pb] VMT-alpha-NET Using a Forward Dosimetric Planning Technique to Treat Refractory or Relapsed Neuroendocrine Tumors
π΅ Active, Not Recruiting Early Phase1 π Investigational Drug / Biologic Sponsor: David Bushnell
π©Ί Plain-English Summary (8th-Grade Level)
This is a safety study to determine the recommended dose to test in clinical trials. The study involves two treatments with 212Pb (212-lead) VMT-Ξ±-NET. This is a safety study only; it will most likely not provide therapeutic benefit.
Who can join: Review the eligibility criteria below.
Location: Holden Comprehensive Cancer Center at the University of Iowa β Iowa City, Iowa
Age range: 18 Years to 80 Years
π§ͺ Interventions in This Study
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (1 Sites)
- Holden Comprehensive Cancer Center at the University of Iowa β Iowa City, Iowa
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neuroendocrine Tumors
- Targeted Alpha-emitter Therapy of PRRT NaΓ―ve and Previous PRRT Neuroendocrine Tumor Patients β Denver, Colorado
- Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors β Hamilton, Ontario
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients β Gilbert, Arizona
- Post-Authorization Long-Term Safety Study of LUTATHERA β Phoenix, Arizona
- Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors β Edmonton, Alberta
Explore by condition: All Neuroendocrine Tumors clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.